The Priority Review

Tag

RRP

1 story

  1. Clinical trials

    Precigen registers Phase 3 study of zopapogene imadenovec in pediatric RRP

    The study, led by Precigen, Inc., plans to enroll 15 participants and has a planned start date of December 31, 2026, with a planned primary completion date of January 2029. It plans to assess the safety and efficacy of zopapogene imadenovec, an investigational immunotherapy, in children with recurrent respiratory papillomatosis.